- Posted Monday April 12, 2010
TGen Drug Development (TD2) partners with Horizon Discovery to offer an integrated personalized medicine service
Alliance aims to define the future of oncology drug
SCOTTSDALE, Ariz., and Cambridge, U.K. - April 12, 2010 - A strategic alliance announced today between TGen Drug Development (TD2) and Horizon Discovery Limited will significantly advance personalized medicine.
The partnership will create a beginning-to-end solution for pharmaceutical and biotechnology companies to more rationally design and tailor their drugs to specific patient populations based on the unique genetic variations that define a given disease.
TD2 will use Horizon's panel of more than 200 genetically-defined human isogenic cell-lines - designed to accurately mirror cancer patient genetics - in its comprehensive pre-clinical service as a prelude to performing selected in-house clinical trials. This will provide clients with a fully integrated drug discovery service that will accelerate the isolation and optimization of appropriately targeted therapeutic agents and attain their rapid market approval. And it will save time and money in the development of more effective cancer treatments.
"The future of oncology drug development will require us to predict which patients will respond to what drug," said Dr. Stephen Gately, TD2's President and Chief Scientific Officer, referring to the goal of personalized medicine - treating patients with drugs tailor-made for their specific diseases.
"This partnership is the engine that will actually make this work and allow for the design of shorter and less-costly clinical trials that enroll the patients most likely to respond to a given drug," Gately said.
Today's agreement between TD2 and Horizon builds on another agreement announced Feb. 2 between Horizon and TD2's parent organization, the Translational Genomics Research Institute (TGen), to develop new human disease models for TGen's cancer research.
"Working with TD2 will enable us to broaden the impact of our GENESIS and X-MAN technologies in the quest for therapies that target the genetic causes of cancer in each patient's tumor," said Dr. Chris Torrance, CEO of Horizon, based in Cambridge, U.K.
Horizon's new GENESIS technology allow researchers, for the first time, to routinely and precisely alter any specific gene or genomic location in a human cell. This would allow, for example, the ability to take a non-cancerous cell and mutate it to create a cancerous cell that matches the mutation in a given patient-s tumor. Researchers then can test potential treatments on the cell pairs to define which specific mutation status confers the maximal drug activity. These engineered lines and their matched controls can be rapidly deployed in target validation, drug screening, patient profiling, drug resistance and drug re-profiling.
TD2 also has the expertise and capabilities to perform de novo high-throughput synthetic lethal screens that targets the nearly 3-billion-letter human genome, the DNA blueprint that makes us who we are. This will enable users to define the next generation of patient-relevant drug targets. Along with TD2's world-class preclinical, clinical and regulatory affairs expertise, it will ensure that client's targets and drugs will move quickly from the laboratory bench to the patient bedside.
TD2 will provide high-throughput screening capabilities, study execution and business marketing, and may incorporate new service offerings that emerge from its affiliated organizations, TGen and the Van Andel Research Institute.
Horizon through its subsidiary Horizon Discovery Services will support the pre-clinical offerings with bespoke 2D and 3D assay formats that closely mimic the in vivo phenotype being driven by primary and secondary genetic cancer mutations. A key part of identifying the correct phenotype is the ability to replicate the context of the mutation in the actual tumour microenvironment.
About Horizon Discovery
Horizon Discovery is a translational genomics and personalized medicine company founded in June 2007 and is headquartered at IQ Cambridge, Cambridge, U.K., and with additional research laboratories in Torino, Italy. Horizon's goal is to convert new information on the genetic causes of cancer into laboratory models that will facilitate the discovery of drugs that target these defects. Central to this aim is Horizon Discovery's offering of X-MAN isogenic cell-lines, which represent accurate models of defined cancer patient populations and their matched normal genetic backgrounds - a missing link in the rational and efficient development of novel targeted anti-cancer agents. These X-MAN models are now being used to speed up and rationalize every phase of the drug development process; from the discovery of cancer targets and biomarkers to the design of more rational clinical trials based around the patients most likely to respond.
Dr. Darrin M. Disley
+44 (0)1223 303049 or +44 (0)7786 133893
TGen Drug Development (TD2), a wholly owned subsidiary of the Translational Genomics Research Institute (TGen), is a 501(c) 3 non-profit organization. TD2 provides innovative services for oncology focused biopharmaceutical companies using a dedicated team of professionals with broad experience and understanding in drug development. TD2 is uniquely positioned to support the need for improved and accelerated development of new chemical entities (NCE's) for life-threatening diseases. TD2 uses a unique combination of experience gained through its contract research organization business, and an integrated suite of proprietary and non-proprietary tools, preclinical study execution, regulatory affairs assistance, clinical trial design and management, and drug development experts to successfully move therapeutics towards regulatory approval. TD2 is dedicated to reducing the risks and uncertainty inherent in the drug development process. For more information, visit www.td2.org.
The Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life changing results. Research at TGen is focused on helping patients with diseases such as cancer, neurological disorders and diabetes. TGen is on the cutting edge of translational research where investigators are able to unravel the genetic components of common and complex diseases. Working with collaborators in the scientific and medical communities, TGen believes it can make a substantial contribution to the efficiency and effectiveness of the translational process. TGen is affiliated with the Van Andel Research Institute in Grand Rapids, Michigan. For more information, visit: www.tgen.org.
TGen Senior Science Writer
# # #